Jazz gam­bles $175M on a triple-pronged armed an­ti­body pact with Im­muno­Gen

Jazz Phar­ma­ceu­ti­cals is team­ing up with Im­muno­Gen on a slate of armed an­ti­bod­ies.

Jazz $JAZZ will pay $175 mil­lion — $75 mil­lion up­front and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.